Javascript must be enabled for this website to work.

#script { display:none; } #noScript{ width: 350px; height: 175px; text-align: center; background: white; padding: 35px; display: block; margin-top: -87px; top: 50%; position: absolute; border-bottom: 1px solid #c2c2c2; border-left: 1px solid #e6e6e6; border-right: 1px solid #e6e6e6; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; margin-left: 50%; left: -175px; } #noScript img{width:100%;} body{background:#f7f7f7;}

respiratory

Asthma

The DP2 pathway: a promising target for new asthma therapies?

Sponsored by Novartis Pharmaceuticals Australia Pty Ltd

22 May 2019

The DP2 receptor pathway has been heralded as a novel and important therapeutic target for asthma. We sat down with Dr David Sandham, from the Novartis Institutes for Biomedical Research in Cambridge, to share the back story on targeting DP2. Dr Sandham was in Australia for the TSANZSRS 2019 Annual Scientific Meeting on the Gold Coast. Why is ...

Already a member?

Enter your email to keep reading.

Not a member yet?

Join now for free, independent news relevant to your specialty. the limbic is intended for practicing health care professionals only.

Title: *

Name: *

Email: *

AHPRA Number: *

Can't remember your AHPRA number? Search for it here

What's your primary area of interest? *

The limbic's weekly newsletter is a round up of key news highlights that's relevant to your specialty. The newsletter may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government and not-for-profit organisations.

You will not receive advertisers only emails and your details will not be shared with any other party.

I would like to receive the limbic newsletter *

I have read and agree to the limbic Terms and Conditions & Privacy Policy *

Cancel